Arcutis Biotherapeutics (NASDAQ:ARQT) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.21) by 4.76 percent. This is a 37.5 percent increase over losses of $(0.32) per share from the same period last year. The company reported quarterly sales of $65.85 million which beat the analyst consensus estimate of $62.25 million by 5.78 percent. This is a 32.84 percent increase over sales of $49.57 million the same period last year.